Compare DMRC & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRC | TNYA |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 171.4M |
| IPO Year | 2008 | 2021 |
| Metric | DMRC | TNYA |
|---|---|---|
| Price | $9.48 | $0.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $5.33 |
| AVG Volume (30 Days) | 276.6K | ★ 3.0M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.58 | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,213,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.69 | N/A |
| 52 Week Low | $4.07 | $0.53 |
| 52 Week High | $17.47 | $2.35 |
| Indicator | DMRC | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 46.31 |
| Support Level | $9.52 | $0.65 |
| Resistance Level | $10.31 | $0.82 |
| Average True Range (ATR) | 1.26 | 0.06 |
| MACD | -0.68 | -0.01 |
| Stochastic Oscillator | 3.78 | 20.38 |
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.